Abbreviations: GPCR, G protein-coupled receptor; GRK2, G protein-coupled receptor kinase 2; IR, insulin resistance; HF, heart 6 failure; HFD, High fat diet; WT, wild type. G protein-coupled receptor kinase 2 (GRK2) has recently emerged as a negative modulator of insulin signalling. GRK2 3 downregulation improves insulin sensitivity and prevents systemic insulin resistance (IR). Cardiac GRK2 levels are increased in 4 human heart failure, while genetically inhibiting GRK2 leads to cardioprotection in mice. However, the molecular basis underlying the 5 deleterious effects of GRK2 up-regulation and the beneficial effects of its inhibition in the heart are not fully understood. Therefore,
INTRODUCTION

46
G protein-coupled receptor kinases (GRKs) were initially identified as serine-threonine kinases able to phosphorylate agonist-47 activated G protein-coupled receptors (GPCRs), triggering the binding of arrestins to the receptor, what impairs G protein coupling in 48 a process known as desensitization [1] . However, very recent findings suggest that the GRK2 isoform is also a key controller of 49 insulin receptor signaling [2] . GRK2 downregulation can prevent the development of metabolic disorders, modulating energy 0 expenditure and brown fat function [3] and also insulin actions in peripheral tissues [2] . Notably, GRK2 +/-mice (expressing 50% less 1 protein than control littermates) show improved systemic insulin sensitivity, display enhanced activation of the insulin-mediated Akt 2 pathway in muscle, adipose tissue and liver, and are resistant to the induction of insulin resistance (IR) in three different mouse 3 models of this condition [2] . Remarkably, such differences in insulin sensitivity between wild type (WT) and GRK2 hemizygous mice 4 were noted in the adult stage but were not evident in young animals [2] .
5
GRK2 has also been described to play a relevant role in cardiovascular physiopathology. Increased cardiac GRK2 levels have been 6 reported in patients with ischemic or idiopathic dilated cardiomyopathy, cardiac ischemia, hypertension, volume overload and left 7 ventricular hypertrophy [1, 4, 5] . Also, enhanced GRK2 expression induced by neurohormonal activation has been associated with 8 lower cardiac function and poorer prognosis in human heart failure (HF) and appears as an early event in maladaptive cardiac 9 remodelling in HF [5] [6] [7] , altogether putting forward GRK2 as a relevant therapeutic target in this myocardial disease (reviewed in ref.
60
[6]). Consistently, genetic inhibition of GRK2 is cardioprotective in different animal models ([1, 5-8] and references therein), and 61 hemizygous GRK2 mice are hyper-responsive to catecholamines and display enhanced cardiac contractility and function, whereas 62 transgenic mice overexpressing different levels of this kinase show an impaired adrenergic cardiac response [9] ). However, the 63 detailed molecular mechanisms and the relevant functional interactions underlying the deleterious effects of elevated GRK2 levels in 64 cardiac function and the beneficial effects of its inhibition remain to be fully established.
65
In principle, up-regulation of GRK2 in HF would further exacerbate the marked β-adrenergic desensitization observed in such 66 condition. However, chronic adrenergic activation appears to be more detrimental than beneficial for heart disease and, most 3 importantly, β-blockers represent a successful standard treatment for this disease. In this context, the fact that GRK2 inhibition acts in 68 a synergic manner with established β-blocker treatments (reviewed in [6, 7] ) suggests these two therapeutic strategies must have 69 independent mechanisms of action. Thus, the functional impact of altered GRK2 levels might also be related to the interactions of this 0 protein with cellular partners other than β-adrenergic receptors [10] .
1
In this regard, adding to the data showing that GRK2 up-regulation inhibits insulin signaling in muscle or adipose tissue [2] , recent 2 findings have suggested that cardiac-specific overexpression of GRK2 inhibits glucose uptake and promotes IR after myocardial 3 ischemia in young mice [11] . However, the potential interconnections among a systemic IR status, GRK2 levels and the cardiac 4 maladaptive remodeling linked to cardiac dysfunction have not been addressed to date.
5
In this report, we have characterized the activation of insulin signaling pathways, tissue remodeling in the heart and 6 cardioprotective gene expression patterns in young and adult WT and GRK2 +/-mice. This experimental model allows us to explore the 7 consequences of a chronic, physiological-range change in GRK2 levels with age (a risk factor for the onset of most cardiovascular 8 pathologies) that would mimic the long sought pharmacological systemic inhibition of GRK2 as a potential drug target. In addition,
9
we have investigated the effect of systemic IR-promoting conditions on cardiac GRK2 levels and its impact on cardiac insulin 0 responses. Our data point at new molecular links between GRK2 up-regulation in IR-related situations and maladaptive cardiac 1 remodeling in the adult mouse heart. 
Co-immunoprecipitation assays
8
Cell lysates obtained as previously described for Western Blot were quantified using the Lowry procedure. Next, 500 µg total protein 9 per lysate were incubated with 10 µl of either rabbit IgG or IRS1 antibody (Santa Cruz Biotechnology, Dallas, TX, USA) and 0.4 0 µg/µl BSA on a rotating shaker at 4°C overnight and 15 µl of Protein G-Sepharose (50% in lysis buffer) were added to each tube.
1
After 2 hours on a rotating shaker at 4°C, tubes were centrifuged at 14000 x g for 5 seconds and the pellets were washed with pre- mRNA from heart tissue of at least 6 WT and 6 GRK2 +/-mice was isolated as described before. RT-PCRs were performed by the 8 Genomic Facility at CBMSO using Light Cycler equipment (Roche, Indianapolis, IN, USA). Microarray validations were performed 9 using both commercial Taqman Gene Expression Assay probes (Applied Biosystems,Life Technologies, Grand Island, NY, USA) and 0 self-designed probes purchased from Sigma with Syber Green technology. qPCRs and statistical analysis of the data were performed 1 by the Genomic Facility at CBMSO using GenEx software. performed with a piPET scanner and tomographic images were reconstructed using a three-dimensional ordered subset expectation 6 maximization algorithm as previously described [15] . Region of interest measurements were made on multiple axial slices of the 7 myocardium and tracer uptake was quantified as standardized uptake values normalized by injected dose and corrected for body 8 weight. 
5
3.1 Decreased GRK2 levels correlate with enhanced cardiac insulin sensitivity 6 GRK2 can act as a negative modulator of insulin receptor signalling pathways, and adult GRK2 +/-mice show improved systemic 7 insulin sensitivity and are resistant to the induction of IR in peripheral tissues [2] . In this context, we explored the possibility that 8 GRK2 dosage could modify heart insulin sensitivity in vivo in 9 month-old mice. The translocation to the plasma membrane of the 9 GLUT4 glucose transporter is a key early event in glucose uptake stimulated by insulin. As can be observed in Figure 1a , insulin-0 dependent GLUT4 translocation was significantly enhanced in adult GRK2 hemizygous mice, compared to wild-type animals, as 1 assessed by Western Blot analysis of membrane fractions of cardiac tissue. These results are in agreement with the increased 2 accumulation of labelled deoxyglucose in the hearts of GRK2 +/-mice quantified by PET (Supplementary Figure 1S) . A similar pattern 3 was observed for the rapid stimulation of Akt and its downstream target p70S6K kinase detected with specific phospho-antibodies 4 upon injection of insulin (Fig. 1b-e) .
Of note, upstream insulin signalling events such as the amount of phospho-Tyrosine(Tyr896)IRS1 was increased in GRK2 +/-hearts 6 after insulin stimulation while the activation status of the ERK cascade was not affected (Supplementary Fig. 1S 
4
We found that GRK2 +/-mice showed a modest but significant increase in heart to body weight ratio and in the total cardiac area with 5 age compared to the change observed in WT animals ( Fig. 2a and 2b) . We also found an enhanced increase in cardiomyocyte diameter 6 in GRK2 +/-animals ( Fig. 2c) , an established indicator of cardiac hypertrophy. No differences in these parameters were found at 4 7 months of age between WT and GRK2 +/-animals. Echocardiographic analysis also revealed a certain degree of hypertrophy in the 9 8 month-old hemizygous mice, mainly referred to left ventricular mass (data not shown) in the absence of any alterations in cardiac 9 functionality, as defined by fractional ejection (EF) or fractional shortening (FS) parameters (Fig. 2d) . Consistently, fibrosis was not 0 increased in either 4 or 9 month-old GRK2 +/-mice compared with age-matched controls (Fig. 2e) .
2
Decreased GRK2 levels correlate with the expression of key genes involved in physiological hypertrophy/cardioprotection 3
Insulin is known to play a protective role in cardiac physiology, via the control of cardiac substrate utilization, cardiomyocyte 4 growth, gene expression, survival and contractility by means of the homeostatic stimulation of the PI3K/Akt and other intracellular 5 signalling pathways [17] . As an unbiased approach to assess the functional consequences of altering GRK2 levels in the modulation 6 of insulin response and heart function, we compared the transcriptional profile of the cardiac tissue of WT and GRK2 +/-mice of 4 or 9 7 months of age using microarray RNA expression techniques without subjecting the animals to prior specific treatments to study the 
GRK2
+/-animals at each group of age (database access number GSE41706) revealed significant differences only at 9 months (33 0 8 genes significantly up-regulated and 28 genes down-regulated in GRK2 +/-mice compared to WT) while no differences between 1 genotypes were detected at 4 months of age (Figure 3a and Suppl. Table 1 ), suggesting that the effects of GRK2 dosage on cardiac 2 gene expression require additional age-related changes to become apparent.
3
We next performed a detailed analysis of the function and characteristics of the up or down-regulated genes. Several interesting 4 patterns were noted. First, GRK2 +/-mice at 9 months of age showed decreased expression of genes described to be up-regulated during 5 pathological heart hypertrophy and/or in well-characterized cardiovascular disease co-morbidities such as diabetes and obesity. Eight 6 out of the 28 genes down-regulated in GRK2 +/-mice (29%) belonged to this group (see Fig. 3b ). This list included the pivotal heart 7 hypertrophy markers Acta1 (skeletal muscle alpha-actin) and the atrial natriuretic factor precursor Nppa [18, 19] negative regulator of insulin signaling [28, 29] were also decreased in 9 month-old GRK2 +/-hearts.
7
A second interesting pattern found in GRK2 +/-mice was that 10 out of 33 genes that were up-regulated in these animals (30%)
8
have been reported to play a protective role in cardiovascular disease and are often down-regulated in pathological heart hypertrophy 9 and/or diabetes/obesity co-morbidities (Fig. 3b) 
2
The third relevant pattern of differential expression detected in GRK2 +/-mice reflects changes in the expression of genes similar to 3 those taking place upon exercise and in situations of physiological heart hypertrophy ( Fig. 3b) . These include the up-regulation of the protein displayed resistance to cardiac failure upon pressure overload [39] . The expression profile of several of the key genes 0 supporting these patterns was validated by qPCR (Suppl. Fig. 2S ).
1
In sum, the microarray analysis detected in GRK2 +/-mice hearts an increased expression of a limited group of important genes 2 related to physiological hypertrophy while the expression of genes key to the development of pathological hypertrophy or related to 3 diabetes/obesity co-morbidities is repressed.
4
Increased cardiac GRK2 expression in adult obese (ob/ob) mice and in high fat diet-fed animals
5
Since GRK2 levels increase in muscle and adipose tissue under insulin resistance-promoting conditions [2] we tested whether this 6 process was also taking place in cardiac tissue. A clear increase in GRK2 protein levels was observed in hearts of 8 month-old ob/ob 7 mice (Fig. 4a) , an age in which this strain of mice is known to manifest cardiac hypertrophy, IR and metabolic alterations involving 8 alterations in the PI3K/Akt axis [41] . This increase in total GRK2 protein levels caused an increment in the amount of GRK2 that 9 could be detected in association with IRS1 (Fig. 4b) , a situation that we have previously described to negatively modulate insulin 0 signaling. GRK2 levels were also increased upon feeding young animals a high fat diet (HFD, Fig. 4c ), a well-established trigger for We have addressed herein the potential interconnections among an IR status, GRK2 dosage and cardiac remodeling by 1 investigating the impact of GRK2 down-modulation on cardiac insulin sensitivity and gene expression patterns, and the effects of 2 systemic insulin resistance-promoting conditions on cardiac GRK2 levels.
3
First, we find that decreased GRK2 levels specifically preserve metabolic and pro-survival signals downstream of insulin (such as 4 the Akt/p70S6K pathway and glucose transport) in the hearts of 9 month-old GRK2 +/-animals, whereas the ERK activation status is 5 not affected. Second, with age, GRK2 down-regulation triggers physiological heart hypertrophy and switches on a cardioprotective 6 gene expression pattern as detected in such adult mice. This pattern is characterized by an increased expression of a limited group of 7 key genes related to physiological hypertrophy, while the expression of genes reported to lead to the development of pathological 8 hypertrophy or related to diabetes/obesity co-morbidities is repressed, compared to WT individuals. Third, we uncover that cardiac 9 GRK2 expression levels increase in situations of systemic insulin resistance, such as in obese mice or after HFD feeding, conditions in 0 which larger amounts of GRK2-IRS1 complexes are formed. Fourth, while insulin resistance develops in the hearts of wild-type mice 1 after HFD feeding, sensitivity to insulin was strongly preserved in GRK2 +/-cardiac tissue.
2
We have previously reported that GRK2 +/-mice are protected against HFD-induced obesity and systemic IR, and we cannot rule 3 out that this global protection may contribute to the observed enhanced insulin signaling in the heart upon a HFD. However, given the 4 enhanced interaction of GRK2 with IRS1 that we find in cardiac tissue of different obese mice models, our data point at an important 5 role for this kinase in negatively regulating insulin signaling in the heart, coherent with what was previously published by Garcia- 
4
The fact that GRK2 downregulation potentiates the insulin-triggered PI3K/Akt pathway in the adult mice heart is then consistent 5 with the mild hypertrophic phenotype conferred by age to GRK2 +/-animals being physiological rather than pathological, This is in 6 agreement with the morphometric analysis and functional results, and with an overall cardio-protective gene expression pattern
7
(decreased presence of pathological genes, enhanced expression of critical protective genes) in the heart of GRK2 +/-9 month-old mice.
8
It is worth noting that GRK2 +/-animals displayed changes in the expression of several genes reported to be similarly modulated by 9 insulin in the heart or other tissues (Nr4a1, Tcfl2, Rrad, Aqp7, Cebpb, Ppargc1b, Egr1) , and a relevant proportion of genes whose 0 expression is altered in hemizygous animals can be related to: i) the modulation of insulin sensitivity; ii) to the PI3K/Akt pathway; iii)
1 to diabetes/obesity-related pathological situations.
2
Insulin activation of the PI3K/Akt cascade is protective in the heart by inhibiting apoptosis and oxidative stress [46] , whereas 3 myocardial IR has been suggested as a key factor in the development of HF [47, 48] . In this context, our results strongly suggest the 4 novel concept that cardiac GRK2 levels could act as an integrative sensor of different pathological inputs and affect cardiac function 5 by simultaneously altering beta-adrenergic and insulin signalling (see suggested model in Fig. 5) . Thus, the increase in cardiac GRK2 6 levels previously reported to take place in myocardial infarction or hypertension as a consequence of excessive neurohormonal 7 stimulation [5, 6] , would also take place as a consequence of insulin resistance-promoting conditions such as a HFD or obesity, by 8 mechanisms that remain to be investigated. Also, enhanced cardiac GRK2 would promote, in addition to the canonical effects 9 described for GPCR signaling, an insulin-resistant state of the heart leading to alterations of key metabolic and cardioprotective 0 pathways [11], further fuelling a dysfunctional cycle and allowing progression to maladaptive remodelling.
1
A detrimental vicious cycle has been postulated [48, 49] in which the compensatory hyper-adrenergic state characteristic of 2 reduced cardiac output would promote lipolysis in the adipose tissue. This would lead to increased circulating levels of free fatty
3
acids, what in turn would inhibit cardiac glucose transport, switching energy substrate use and triggering heart lipotoxicity.
4
Conversely, many mechanisms have been suggested to explain the increased incidence of HF in diabetic patients, including 5 hyperinsulinemia, hyperglycemia, lipotoxicity, obesity, vascular alterations, increased oxidative stress or hyperactivation of 6 neurohumoral systems ([47, 48, 50] and references therein). Our data suggest that GRK2 could participate as an important integrative 7 node in such complex mechanisms linking HF, diabetes and IR.
8
Such central role of GRK2 also fosters its potential as a therapeutic target and diagnostic marker. Our study suggests that strategies 9 leading to a systemic reduction in GRK2 levels/function, even when used in a sustained temporal frame and in adult tissue, could 0 facilitate the activation of defined cardioprotective routes, such as the insulin pathway. This would promote a physiological 1 hypertrophy-like gene expression pattern that could contribute to explain the beneficial outcome of GRK2 inhibition.
3 11
This discovery could help explain the reported reinforcement between the therapeutic effects of down-regulating cardiac 4 adrenergic input (using beta-blockers) and GRK2 down-modulation.
5
Since our data and previous report by other laboratories [1, 6, 7] indicate that reduced GRK2 revels are beneficial for cardiac 6 function and also for maintaining vascular tone [4] , and systemic insulin sensitivity [2] , it could be argued that GRK2 hemizygosity 7 would confer an overall benefit. However, the fact that a GRK2 +/+ genotype has been positively selected for by evolution suggest that 8 the expression level generated by such genotype must be overall adaptative. Nevertheless, unlimited food availability, a condition that 9 humans nowadays share with caged animals, was not at all present during evolution and therefore this might explain why GRK2 0 downregulation was not selected for.
1
GRK2 inhibition has been shown, in mouse models, to delay the reduction in glucose uptake and preserve insulin signalling in the 2 heart after myocardial ischemia [11] No genes were found to change significantly at 4 months of age, but, at 9 months of age, 61 genes were significantly different between WT and GRK2 +/-mice. Black, genes whose expression is increased in GRK2 +/-vs WT. Grey, genes whose expression is reduced in GRK2 +/-vs WT. b) The table depicts genes reported to be upregulated during pathological heart hypertrophy or during comorbidities such as diabetes/obesity (see references in the text) found to be downregulated in adult GRK2
+/-mice vs WT heart microarray, or genes for which the inverse relationship occurs (left panel). Also, a list of genes upregulated/downregulated in the array and also during physiological heart hypertrophy or response to exercise is specified (right panel).
Figure 4
Lucas and Jurado-Pueyo et al Figure 4 . Expression of the GRK2 protein is increased in myocardial tissue of obese or high fat diet-fed mice which correlates with higher levels of IRS1/GRK2 complexes, whereas GRK2 +/-animals are resistant to high fat diet-induced insulin resistance in cardiac tissue. a) The expression levels of GRK2 were analyzed by Western Blot in cardiac tissue of 8 month-old ob/ob or WT mice and quantified by densitometry analysis. Results were normalized by GAPDH protein levels and expressed as percent over control (WT mice) (N= 5). b) Total protein from heart tissue (500 µg) was immunoprecipitated with the anti-IRS1 or anti-IgG antibodies, and the resulting immune complexes were analyzed by Western blot with the corresponding antibodies against GRK2 and IRS1.(N=3). Precipitated GRK2 amount was normalized with immunoprecipitated IRS1 amount. Same for 3 month-old HFD-fed mice represented over standard diet-fed animals in (c) and (d) (N= 9). Representative blots are shown. Data are mean±SEM of the indicated independent experiments *,p<0.05; **,p<0.01. e) Representative Western Blots of the specified phosphoproteins and controls in heart tissue after 12 weeks of HFD feeding or SD and 3 min insulin injection in WT or GRK2 +/-mice. (f) Quantification of Akt phosphorylation (Ser473), p70S6K phosphorylation (Thr389) or ERK1/2 phosphorylation (Thr202/Tyr204) in cardiac tissue lysates of WT and GRK2+/-mice after 12 weeks of HFD feeding after an intravenous injection of insulin for 3 minutes (N= 3-4). Results are expressed as fold increase over basal (untreated mice). Statistical analysis was performed using T-test. Data are mean±SEM of the indicated independent experiments.+++p<0.001;+p<0.05 referred to basal (untreated mice); **p<0.01; *p<0.05 referred to fold increase upon insulin stimulation over HFD fed WT mice. situations would not only lead to a decrease in β-AR responsiveness, but also in insulin signaling thus promoting a pathological increase in the neurohumoral stimulation of the heart, and also lead to IR thus aggravating this condition. GRK2-promoted transcription reprogramming would also impinge upon both processes.
Supplemental Table 1S . Detailed list of genes showing differential expression between WT and GRK2 +/-adult hearts.
SUPPLEMENTAL TABLES AND FIGURES
Genes whose expression varied with an FDR<0.2 and a Fold change >1.5 or <-1.5 are listed.
